Skip to main content

Colds and Cancer

Premium

There is no cure for the common cold, but for cancer patients, that may be a good thing. In a new study in Science Translational Medicine, researchers from Leeds University and the Institute of Cancer Research in the UK describe a method that uses the common cold virus to kill tumors and trigger an anti-cancer immune response in patients, reports Reuters' Kate Kelland. The team conducted the study on 10 patients with advanced bowel cancer with liver metastases who were due to have surgery. They gave the patients up to five doses of an experimental reovirus vaccine therapy and later confirmed in tissue samples that the virus had targeted and become active in the cancerous tissue while leaving normal liver tissue alone, Kelland says. Not only did the virus attack cancer cells, it also caused the body's immune system to kill off any remaining cancer cells.

"By hitching a ride on blood cells, the virus was protected from antibodies in the blood stream that might otherwise neutralize its cancer-fighting abilities," she adds. "The findings suggest viral therapies like this, called reovirus, could be injected into the blood stream at routine outpatient appointments — like standard chemotherapy — making them potentially suitable for treating a range of cancers."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.